AIMS: The prognosis of metaplastic breast cancer (MBC) is reportedly worse than that of triple-negative invasive ductal carcinoma (TN-IDC), but the determinants of poor prognosis are not yet known. METHODS: Patients from two Korean cancer centres were included in this study (67 MBC and 520 TN-IDC). Characteristics of the two disease groups, including clinical parameters, histological features, chemoresponsiveness, disease recurrence and survival estimates, were evaluated. RESULTS: MBC presented with larger tumours, more frequent distant metastasis and higher histological grade compared with TN-IDC (p<0.001). All but nine patients with MBC had triple-negative disease. Disease-free survival and overall survival (OS) of MBC were worse than TN-IDC (p<0.001). Multivariable analysis of disease-free survival revealed MBC type as an independent prognostic factor (HR 2.53; 95% CI 1.32 to 4.84) along with lymph node metastasis and implementation of breast conserving surgery. For OS, MBC type remained a significant prognostic factor (HR 2.56; 95% CI 1.18 to 5.54). Chemoresponsiveness of MBC and TN-IDC were similar in both neoadjuvant (p=1.000) and advanced disease settings (p=0.508). For a given MBC type, risk factors for disease recurrence included the presence of a squamous component (HR 4.0; 95% CI 1.46 to 10.99) and lymph node metastasis (HR 4.76; 95% CI 1.67 to 13.60); the risk factor for OS was initial distant metastasis (HR 10.77; 95% CI 2.59 to 44.76). CONCLUSIONS: MBC had worse survival outcomes compared with TN-IDC. Poor prognosis for MBC was likely caused by frequent recurrence with high initial stage and the unique biology of MBC itself.
AIMS: The prognosis of metaplastic breast cancer (MBC) is reportedly worse than that of triple-negative invasive ductal carcinoma (TN-IDC), but the determinants of poor prognosis are not yet known. METHODS:Patients from two Korean cancer centres were included in this study (67 MBC and 520 TN-IDC). Characteristics of the two disease groups, including clinical parameters, histological features, chemoresponsiveness, disease recurrence and survival estimates, were evaluated. RESULTS:MBC presented with larger tumours, more frequent distant metastasis and higher histological grade compared with TN-IDC (p<0.001). All but nine patients with MBC had triple-negative disease. Disease-free survival and overall survival (OS) of MBC were worse than TN-IDC (p<0.001). Multivariable analysis of disease-free survival revealed MBC type as an independent prognostic factor (HR 2.53; 95% CI 1.32 to 4.84) along with lymph node metastasis and implementation of breast conserving surgery. For OS, MBC type remained a significant prognostic factor (HR 2.56; 95% CI 1.18 to 5.54). Chemoresponsiveness of MBC and TN-IDC were similar in both neoadjuvant (p=1.000) and advanced disease settings (p=0.508). For a given MBC type, risk factors for disease recurrence included the presence of a squamous component (HR 4.0; 95% CI 1.46 to 10.99) and lymph node metastasis (HR 4.76; 95% CI 1.67 to 13.60); the risk factor for OS was initial distant metastasis (HR 10.77; 95% CI 2.59 to 44.76). CONCLUSIONS:MBC had worse survival outcomes compared with TN-IDC. Poor prognosis for MBC was likely caused by frequent recurrence with high initial stage and the unique biology of MBC itself.
Authors: Cecilia T Ong; Brittany M Campbell; Samantha M Thomas; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Jeremy Force; Allison Hall; Terry Hyslop; E Shelley Hwang; Oluwadamilola M Fayanju Journal: Ann Surg Oncol Date: 2018-05-31 Impact factor: 5.344
Authors: Charlotte K Y Ng; Salvatore Piscuoglio; Felipe C Geyer; Kathleen A Burke; Fresia Pareja; Carey A Eberle; Raymond S Lim; Rachael Natrajan; Nadeem Riaz; Odette Mariani; Larry Norton; Anne Vincent-Salomon; Y Hannah Wen; Britta Weigelt; Jorge S Reis-Filho Journal: Clin Cancer Res Date: 2017-02-02 Impact factor: 12.531
Authors: Julia A Beaver; Danijela Jelovac; Sasidharan Balukrishna; Rory Cochran; Sarah Croessmann; Daniel J Zabransky; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Brian G Blair; David Chu; Timothy Burns; Michaela J Higgins; Vered Stearns; Lisa Jacobs; Mehran Habibi; Julie Lange; Paula J Hurley; Josh Lauring; Dustin VanDenBerg; Jill Kessler; Stacie Jeter; Michael L Samuels; Dianna Maar; Leslie Cope; Ashley Cimino-Mathews; Pedram Argani; Antonio C Wolff; Ben H Park Journal: Clin Cancer Res Date: 2014-02-06 Impact factor: 12.531
Authors: Aron Gortman; Noel J Aherne; Justin Westhuyzen; Julan V Amalaseelan; Patrick M Dwyer; Matthew Hoffmann; Andrew T Last; Thomas P Shakespeare Journal: Mol Clin Oncol Date: 2021-07-01